shopify site analytics
Canadian Life Sciences Database

Oncolytics Biotech Inc.

Company
Therapeutics (1)  More information available with subscription
Clinical trials (10)  More information available with subscription
Management (12)  More information available with subscription
Financing (11)  More information available with subscription
License agreements (5)  More information available with subscription

Profile sponsored by:

General information
Oncolytics Biotech Inc.
210, 1167 Kensington Crescent NW
T2N 1X7 Calgary, Alberta
Canada

Contact person: Michael Moore, VP Investor Relations and Corporate Communications
Company main phone: +1 (403) 6707377
Company main fax:  +1 (403) 2830858
Email:  [Available with subscription]
Website:  www.oncolyticsbiotech.com
Member:
Year founded:1998
Source of foundation:Independent foundation
Corporate description / mission:
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. 
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Other
  • Drug delivery
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
On the market:1
Description of products:
Pelareorep
Special IP situation:
Oncolytics have more than 396 patents issued globally, including more than 49 in the U.S. and 21 in Canada, as well as over 29 applications pending worldwide.
Financing details
Market cap. / valuation:CAD 11.90M
Money raised to date:USD 116.27M
Financing details:
Market capitalization as on 21 Oct 2019.

Want to learn more about this company?

More information about Oncolytics Biotech Inc. is available on Biotechgate: Access our global life science database with over 40,000 detailed company profiles.
X